| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5a949d27c44ffcf40bfa6df41eda0f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5263b6ea3b63336201087c6c2ab77d30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59a64c96b008aa6505548acb3cc0fa68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97f4ef25a5e0fe06753b887e55a57b6f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 |
| filingDate |
2013-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_537dc819596dd13a5ea4a93a85875ad6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2466c82d30790ca784c518652c6c1cd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c418a69c0e0c87d545254d509a60455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e41f7fa0d553d4ba7a964428714ef9de |
| publicationDate |
2022-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2876883-C |
| titleOfInvention |
Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| abstract |
The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions. |
| priorityDate |
2012-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |